PropThink: Acadia’s Value Heavily Dependent On Pimavanserin Data

PropThink: Acadia’s Value Heavily Dependent On Pimavanserin Data

[ACN Newswire] – By Jason Napodano, CFAWhen Acadia Pharmaceuticals (NASDAQ:ACAD) held its third quarter conference call on Nov 5, 2012 ( webcast link ) management noted that top-line data from the company’s phase 3 trial, … more

View todays social media effects on ACAD

View the latest stocks trending across Twitter. Click to view dashboard

Share this post